The University of Southampton
University of Southampton Institutional Repository

Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing

Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing
Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing
Disease-causing mutations in mitochondrial DNA (mtDNA) are typically heteroplasmic and therefore interpretation of genetic tests for mitochondrial disorders can be problematic. Detection of low level heteroplasmy is technically demanding and it is often difficult to discriminate between the absence of a mutation or the failure of a technique to detect the mutation in a particular tissue. The reliable measurement of heteroplasmy in different tissues may help identify individuals who are at risk of developing specific complications and allow improved prognostic advice for patients and family members. We have evaluated Pyrosequencing technology for the detection and estimation of heteroplasmy for six mitochondrial point mutations associated with the following diseases: Leber's hereditary optical neuropathy (LHON), G3460A, G11778A, and T14484C; mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS), A3243G; myoclonus epilepsy with ragged red fibers (MERRF), A8344G, and neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP)/Leighs: T8993G/C. Results obtained from the Pyrosequencing assays for 50 patients with presumptive mitochondrial disease were compared to those obtained using the commonly used diagnostic technique of polymerase chain reaction (PCR) and restriction enzyme digestion. The Pyrosequencing assays provided accurate genotyping and quantitative determination of mutational load with a sensitivity and specificity of 100%. The MELAS A3243G mutation was detected reliably at a level of 1% heteroplasmy. We conclude that Pyrosequencing is a rapid and robust method for detecting heteroplasmic mitochondrial point mutations.
1090-6576
190-199
White, Helen E.
2181c0b9-fc3b-407e-95eb-3510524603e5
Durston, Victoria J.
7336d597-984a-4ad4-8be4-886b22705061
Seller, Anneke
65633984-704d-40b1-aa56-03a4d717fccc
Fratter, Carl
1b6ff36c-09e1-471c-a9c7-90f4bfdba953
Harvey, John F.
b27b83e2-c681-4a87-9ce9-7686fc1bba36
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
White, Helen E.
2181c0b9-fc3b-407e-95eb-3510524603e5
Durston, Victoria J.
7336d597-984a-4ad4-8be4-886b22705061
Seller, Anneke
65633984-704d-40b1-aa56-03a4d717fccc
Fratter, Carl
1b6ff36c-09e1-471c-a9c7-90f4bfdba953
Harvey, John F.
b27b83e2-c681-4a87-9ce9-7686fc1bba36
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4

White, Helen E., Durston, Victoria J., Seller, Anneke, Fratter, Carl, Harvey, John F. and Cross, Nicholas C.P. (2005) Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing. Genetic Testing, 9 (3), 190-199. (doi:10.1089/gte.2005.9.190).

Record type: Article

Abstract

Disease-causing mutations in mitochondrial DNA (mtDNA) are typically heteroplasmic and therefore interpretation of genetic tests for mitochondrial disorders can be problematic. Detection of low level heteroplasmy is technically demanding and it is often difficult to discriminate between the absence of a mutation or the failure of a technique to detect the mutation in a particular tissue. The reliable measurement of heteroplasmy in different tissues may help identify individuals who are at risk of developing specific complications and allow improved prognostic advice for patients and family members. We have evaluated Pyrosequencing technology for the detection and estimation of heteroplasmy for six mitochondrial point mutations associated with the following diseases: Leber's hereditary optical neuropathy (LHON), G3460A, G11778A, and T14484C; mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS), A3243G; myoclonus epilepsy with ragged red fibers (MERRF), A8344G, and neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP)/Leighs: T8993G/C. Results obtained from the Pyrosequencing assays for 50 patients with presumptive mitochondrial disease were compared to those obtained using the commonly used diagnostic technique of polymerase chain reaction (PCR) and restriction enzyme digestion. The Pyrosequencing assays provided accurate genotyping and quantitative determination of mutational load with a sensitivity and specificity of 100%. The MELAS A3243G mutation was detected reliably at a level of 1% heteroplasmy. We conclude that Pyrosequencing is a rapid and robust method for detecting heteroplasmic mitochondrial point mutations.

This record has no associated files available for download.

More information

Published date: 2005

Identifiers

Local EPrints ID: 25037
URI: http://eprints.soton.ac.uk/id/eprint/25037
ISSN: 1090-6576
PURE UUID: e25cd27a-da00-4d52-b0ac-4a49183a7984
ORCID for Nicholas C.P. Cross: ORCID iD orcid.org/0000-0001-5481-2555

Catalogue record

Date deposited: 04 Apr 2006
Last modified: 16 Mar 2024 03:23

Export record

Altmetrics

Contributors

Author: Helen E. White
Author: Victoria J. Durston
Author: Anneke Seller
Author: Carl Fratter
Author: John F. Harvey

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×